A previous report shows that targeting B cells with rituximab results in a decrease in rheumatoid factor and serum ACPA levels in RA patients [99], however, we should keep in mind that not all B cells in RA patients are pathogenic and precise deletion of autoreactive B cells may achieve optimal outcomes with minimal adverse effects [100]. Here, PRTN3 is linked to rheumatoid arthritis.